Office of Director

Staff

Director: Yoshiro SAITO, Ph.D. (E-mail: yoshiro @ nihs.go.jp) please remove space back and forth of @

 

Guest Researcher: Ryuichi HASEGAWA, Ph.D. (former Division Head)

Guest Researcher: Ryo TAGUCHI, Ph.D. (Professor of Chubu University)

Guest Researcher: Makoto ARITA, PhD. (Associate Professor, University of Tokyo)

Guest Researcher: Mitsuo SAITO, PhD. (Associate Professor of Teikyo Heisei University, former senior researcher)

Guest Researcher: Susumu KODAMA, PhD. (Assistant Professor of Tohoku University)

Guest Researcher: Hiroki NAKANISHI, PH.D. (Assistant Professor of Akita University)

Guest Researcher: Yoko TAJIMA, MSc. (Assistant Professor of Nagoya City University)

Guest Researcher: Takayoshi Toriyabe, PhD. (Safety Division 2, Pharmaceutical Medical Devices Agency)

Clerical assistant: Chie Sudo


Metabolome Project

Researcher: Masaki Ishikawa, MS

 

Recent Publications

2012

  1. Kurose K, Koizumi T, Nishikawa J, Maekawa K, Saito Y.: Quality requirements for genomic DNA preparations and storage conditions for a high-density oligonucleotide microarray. Biol Pharm Bull. 35: 1846-1848 (2012).
  2. Duan H, Yoshimura K, Kobayashi N, Sugiyama K, Sawada J, Saito Y, Morisseau C, Hammock BD, Akatsuka T.: Development of monoclonal antibodies to human microsomal epoxide hydrolase and analysis of "preneoplastic antigen"-like molecules. Toxicol Appl Pharmacol. 260: 17-26 (2012).
  3. Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H.: Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer. Biol Pharm Bull. 35: 717-724 (2012).
  4. Sudo C, Maekawa K, Kaniwa N, Segawa K, Saito Y: Current status of drug-induced liver disease based on reports of adverse reactions to PMDA in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. in press.
  5. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y.: Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Res. in press.
  6. Tada M, Ishii-Watabe A, Maekawa K, Fukushima-Uesaka H, Kurose K, Suzuki T, Kaniwa N, Sawada JI, Kawasaki N, Nakajima TE, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Okuda H, Hamaguchi T, Saito Y, Matsumura Y.: Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant. Immunogenetics. in press.
  7. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, Hasegawa R, Aihara M, Matsunaga K, Abe M, Furuya H, Takahashi Y, Ikeda H, Muramatsu M, Ueta M, Sotozono C, Kinoshita S, Ikezawa Z.: A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. in press.

2011

  1. Sato Y, Yamamoto N, Kunitoh H, Ohe Y, Minami H, Laird NM, Katori N, Saito Y, Ohnami S, Sakamoto H, Sawada JI, Saijo N, Yoshida T, Tamura T.: Genome-Wide Association Study on Overall Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel., J Thorac Oncol., 6: 132-138 (2011).
  2. Saito Y, Yamamoto N, Katori N, Maekawa K, Fukushima-Uesaka H, Sugimoto D, Kurose K, Sai K, Kaniwa N, Sawada JI, Kunitoh H, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Okuda H, Tamura T.: Genetic polymorphisms and haplotypes of POR encoding cytochrome P450 oxidoreductase in a Japanese population. Drug Metab. Pharmacokinet., 26: 107-116 (2011)..
  3. Hanioka N, Matsumoto K,Saito Y and Narimatsu S: Influence of CYP2C8*13 and CYP2C8*14 Alleles on Amiodarone N-Deethylation. Basic Clin. Pharmacol. Toxicol., 108: 359-362 (2011)..
  4. Sai K. and Saito Y.: Ethnic differences in the metabolism and responses (toxicology and efficacy) of three anti-cancer drugs. Expert Opin. Drug Metab. Toxicol., 7: 967-988 (2011).
  5. Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Kamatani N, Ura T, Saito M, Muro K, Fuse N, Yoshino T, Doi T, Otsu A, Saijo N, Sawada J, Okuda H, Matsumura Y.: Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. Drug Metab Pharmacokinet., 26:  646-658 (2011).
  6. atori N, Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Yomota C, Kawanishi T, Nishimaki-Mogami T, Naito M, Sawada JI, Kunitoh H, Nokihara H, Sekine I, Ohe Y, Yoshida T, Matsumura Y, Saijo N, Yamamoto N, Okuda H, Tamura T.: Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients. J Pharm Sci. 100: 4546-4559 (2011).
  7. Sudo C, Azuma Y, Maekawa K, Kaniwa N, Sai K, Saito Y: Current movements of four serious adverse events induced by medicinal drugs based on spontaneous reports in Japan. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 129: 111-117 (2011)

2010

  1. Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.: Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother Pharmacol. 66: 95-105 (2010).
  2. Matsubara J, Ono M, Honda K, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Shoji A, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Survival prediction for pancreatic cancer patients receiving gemcitabine treatment. Mol Cell Proteomics. 9: 695-704 (2010).
  3. Ikeda H., Takahashi Y., Yamazaki E., Fujiwara T., Kaniwa N., Saito Y., Aihara M., Kashiwagi M. and Muramatsu M.: HLA-class ? markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 51: 297-300 (2010).
  4. Sugiyama E., Kaniwa N., Kim S.R., Hasegawa R.,Saito Y., Ueno H.COkusaka T., Ikeda M., Morizane C., Kondo S., Yamamoto N., Tamura T., Furuse J., Ishii H., Yoshida T., Saijo N. and Sawada J.: Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: Impact of genetic polymorphisms. Clin. Pharmacokinet., 49: 549-558 (2010).
  5. Hanioka N., Matsumoto K.,Saito Y. and Narimatsu S.: Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel.  Basic Clin. Pharmacol. Toxicol., 107: 565-569 (2010).
  6. Sai K.,Saito Y., Tatewaki N., Hosokawa M., Kaniwa N., Nishimaki-Mogami T., Naito M., Sawada J., Shirao K., Hamaguchi T., Yamamoto N., Kunitoh H., Tamura T., Yamada Y., Ohe Y., Yoshida T., Minami H., Ohtsu A., Matsumura Y., Saijo N., Okuda H.: Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients. Br. J. Clin. Pharmacol., 70: 222-233 (2010).
  7. Maekawa K., Harakawa N., Yoshimura T., Kim S.R., Fujimura Y., Aohara F., Sai K., Katori N., Tohkin M., Naito M., Hasegawa R., Okuda H., Sawada J., Niwa T. and Saito Y.: CYP3A4*16 and CYP3A4*18 Alleles Found in East Asians Exhibit Differential Catalytic Activities for Seven CYP3A4 Substrate Drugs. Drug metab. Dispos., 38: 2100-2104 (2010).
  8. Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R.: Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab. Pharmacokinet., 25: 122-133 (2010).
  9. Ishii-Watabe A, Saito Y, Suzuki T, Tada M, Ukaji M, Maekawa K, Kurose K, Kaniwa N, Sawada JI, Kawasaki N, Yamaguchi T, Eguchi Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Hamaguchi T, Okuda H, Matsumura Y.: Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis. Drug Metab. Pharmacokinet., 25: in press (2010).

2009

  1. Ueno H, Kaniwa N, Okusaka T, Ikeda M, Morizane C, Kondo S, Sugiyama E, Kim SR, Hasegawa R, Saito Y, Yoshida T, Saijo N, Sawada J.: Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients. Br J Cancer, 100: 870-873 (2009).
  2. Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T.: Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J Clin Oncol, 27: 2261-2268 (2009).
  3. Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J.: Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica, 39: 140-147 (2009).
  4. Tatewaki N, Maekawa K, Katori N, Kurose K, Kaniwa N, Yamamoto N, Kunitoh H, Ohe Y, Nokihara H, Sekine I, Tamura T, Yoshida T, Saijo N, Saito Y, Sawada J.: Genetic variations and haplotype structures of the glutathione S-transferase genes, GSTT1 and GSTM1, in a Japanese patient population. Drug Metab Pharmacokinet., 24: 118-126 (2009).
  5. Sato Y, Laird NM, Nagashima K, Kato R, Hamano T, Yafune A, Kaniwa N, Saito Y, Sugiyama E, Kim SR, Furuse J, Ishii H, Ueno H, Okusaka T, Saijo N, Sawada JI, Yoshida T.: A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studies. Pharmacogenomics J. 9: 137-146 (2009)
  6. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Minami H, Ohtsu A, Matsumura Y, Saijo N, Sawada J.: Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos., 37: 272-276 (2009).
  7. Sai K., Minami H., Saito Y. and Sawada J.: Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment.  Pharmacogenomics, Anticancer Drug Discovery, and Response (ed. F. Innocenti), Human Press, Totawa NJ, 2009, pp. 267-286.
  8. Sugiyama E, Lee SJ, Lee SS, Kim WY, Kim SR, Tohkin M, Hasegawa R, Okuda H, Kawamoto M, Kamatani N, Sawada J, Kaniwa N, Saito Y, Shin JG.: Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene. Drug Metab Pharmacokinet. 24: 553-556 (2009).
  9. Fukushima-Uesaka H, Saito Y, Maekawa K, Kurose K, Sugiyama E, Katori N, Kaniwa N, Hasegawa R, Hamaguchi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, Yoshida T, Yamamoto N, Nokihara H, Kunitoh H, Ohe Y, Tamura T, Ura T, Saito M, Muro K, Doi T, Fuse N, Yoshino T, Ohtsu A, Saijo N, Matsumura Y, Okuda H, Sawada J.: Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab Pharmacokinet. 24: 565-574 (2009).

2008

  1. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R; JSAR research group.: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 9: 1617-1622 (2008).
  2. Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Ikeda M, Morizane C, Yamamoto N, Yoshida T, Kamatani N, Furuse J, Ishii H, Saijo N, Ozawa S, Sawada J.: Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK). Drug Metab Pharmacokinet., 23:379-384 (2008).
  3. Hanioka N., Tsuneto Y., Saito Y., Maekawa K., Sawada J., Narimatsu S.: Influence of CYP2C19*18 and CYP2C19*19 Alleles on Omeprazole 5-Methylhydroxylation: In Vitro Functional Analysis of Recombinant Enzymes Expressed in Saccharomyces cerevisiae.Basic Clin. Pharmacol. Toxicol., 102: 388-393 (2008).
  4. Sai K., Saito Y., Sakamoto H., Shirao K., Kurose K., Saeki M., Ozawa S., Kaniwa N., Hirohashi S., Saijo N., Sawada J., Yoshida T.: Importance of UDP-glucuronosyltransferase 1A1 *6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett., 261: 165-171 (2008).
  5. Sai K., Saito Y., Itoda M., Fukushima-Uesaka H., Ozawa S., Kurose K., Kaniwa N.,  Kawamoto M., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Yamada Y., Tamura T., Yoshida T., Minami H., Matsumura Y., Ohtsu A., Saijo  N., J. Sawada: Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population. Drug. Metab. Pharmacokinet., 23: 139-147 (2008).
  6. Sai K., Saito Y., Fukushima-Uesaka H., Kurose K., Kaniwa N., Kamatani N., Shirao K., Yamamoto N., Hamaguchi T., Kunitoh H., Ohe Y., Tamura T., Yamada Y., Minami H., Ohtsu A., Yoshida T., Saijo N., Sawada J.: Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother. Pharmacol., 62: 529-537 (2008).
  7. Yin T., Maekawa K., Kamide K., Saito Y., Hanada H., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., Otsuki T., Horio T., Takiuchi S., Kawano Y., Minematsu K., Naritomi H., Tomoike H., Sawada J., Miyata T.: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens. Res., 31: 1549-1557 (2008).